Table 1.
Summary of approved drugs in hypoxia-targeted therapeutics
| Disease classification | Medicine name | Drug category | Stage | Typical example | Reference | |
|---|---|---|---|---|---|---|
| Tumor | Belzutifan | HIF-2α specific antagonist | Approved by FDA | Renal cell carcinoma | 453–455 | |
| Oxaliplatin | DNA synthesis inhibitor | Approved by FDA | Colorectal cancer and liver cancer | 468,469 | ||
| Cardiovascular diseases | Molidustat | Prolyl hydroxylase inhibitor (PHI) | Approved by PMDA | CKD and diabetic heart | 487,488 | |
| Bosentan | Endothelin receptor antagonist | Approved by FDA | Raynaud syndrome | 491 | ||
| Metabolic diseases | Diabetes | Luseogliflozin | SGLT2 antagonist | Approved by PMDA | Diabetic nephropathy | 500 |
| Chronic renal disease | Roxadustat | Prolyl hydroxylase inhibitor (PHI) | Approved by NMPA | Anemia in patients with CKD | 509–511 | |
| Daprodustat | Prolyl hydroxylase inhibitor (PHI) | Approved by MHLW | Anemia in patients with CKD | 513,514 | ||
| Infectious diseases | Respiratory infections | Roxadustat | Prolyl hydroxylase inhibitor (PHI) | Approved by NMPA | COVID-19 | 515 |
FDA the United States (U.S.) Food and Drug Administration, PMDA Pharmaceuticals and Medical Devices Agency of Japan, NMPA National Medical Products Administration of China, MHLW Ministry of Health, Labour and Welfare of Japan